Zobrazeno 1 - 8
of 8
pro vyhledávání: '"Amale Hawi"'
Publikováno v:
Metabolites, Vol 14, Iss 9, p 471 (2024)
Nalbuphine (NAL) is a mixed κ-agonist/μ-antagonist opioid with extensive first-pass metabolism. A phase 1 open-label study was conducted to characterize the pharmacokinetics (PKs) of NAL and select metabolites following single oral doses of NAL ext
Externí odkaz:
https://doaj.org/article/a2246a2e93ae4384bca4a04e32f3edc8
Publikováno v:
British Journal of Clinical Pharmacology.
Population pharmacokinetic (PK) and pharmacokinetic- pharmacodynamic (PK-PD) models were used to quantify the exposure-response (E-R) relationship between nalbuphine exposure and 2 widely used rating scales for itch: the Numerical Rating Scale for th
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::d65659c821ab60205d63bd855b9d4d69
https://doi.org/10.22541/au.166177100.03899983/v1
https://doi.org/10.22541/au.166177100.03899983/v1
Autor:
William D. Shrader, Steven M. Willi, Amale Hawi, M. Grazia Cotticelli, Eric Deutsch, Karlla W. Brigatti, Patrice Rioux, Olena Kucheruk, Guy M. Miller, Thomas Sciascia, David A. Lynch, Robert B. Wilson
Publikováno v:
Movement Disorders. 27:1026-1033
This study tested the ability of A0001 (α-tocopheryl quinone; EPI-A0001), a potent antioxidant, to improve in vitro measures, glucose metabolism, and neurological function in Friedreich ataxia. We used an in vitro study of protection from cell toxic
Publikováno v:
BMC Nephrology
Background Uremic pruritus is a common and deleterious condition among hemodialysis (HD) patients. Central gating of μ/κ opiate circuitry plays an important role in mediating and countering pruritogenic sensation. The objective of this study was to
Autor:
David R, Lynch, Steven M, Willi, Robert B, Wilson, M Grazia, Cotticelli, Karlla W, Brigatti, Eric C, Deutsch, Olena, Kucheruk, William, Shrader, Patrice, Rioux, Guy, Miller, Amale, Hawi, Thomas, Sciascia
Publikováno v:
Movement disorders : official journal of the Movement Disorder Society. 27(8)
This study tested the ability of A0001 (α-tocopheryl quinone; EPI-A0001), a potent antioxidant, to improve in vitro measures, glucose metabolism, and neurological function in Friedreich ataxia. We used an in vitro study of protection from cell toxic
Publikováno v:
Journal of clinical pharmacology. 52(1)
A0001 (α-tocopherylquinone) is a potent antioxidant currently in development for the treatment of symptoms associated with inherited mitochondrial disorders. A0001 pharmacokinetics were studied in a single-blind, adaptive design study following a si
Publikováno v:
Journal of the Chemical Society, Chemical Communications. :283
Acid-catalysed decomposition of (4′-azidophenyl)propanoic and butyric acids leads to ipso-attack by the carboxy group para to the nitrenium ion and the formation of imines of cyclohexadienone spiro-lactones, which can rearrange to the benz-fused la